Management of oral and gastrointestinal mucosal injury: ESMO Clinical Practice Guidelines for diagnosis, treatment, and follow-up
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
Oral and gastrointestinal mucositis caused by high-dose chemotherapy and/or radiation continues to be an important clinical problem. Fortunately, there have been strategic advances over the past decade in understanding the molecular basis of the injury, providing opportunities for the development of drugs and devices to manage toxicity. The guidelines detailed below represent updates from the version published in the 2011 Annals of Oncology [1.Peterson D.E. Bensadoun R.J. Roila F. Management of oral and gastrointestinal mucositis: ESMO Clinical Practice Guidelines.Ann Oncol. 2011; 22: vi78-vi84Abstract Full Text Full Text PDF PubMed Scopus (183) Google Scholar], which were primarily based on the previous version of the guidelines produced by the Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society for Oral Oncology (MASCC/ISOO) [2.Keefe D.M. Schubert M.M. Elting L.S. et al.Updated clinical practice guidelines for the prevention and treatment of mucositis.Cancer. 2007; 109: 820-831Crossref PubMed Scopus (606) Google Scholar]. Three key advances have occurred in the four years following publication of the previous ESMO mucositis guidelines. Each of these advances (listed below) have been completed at the international, inter-professional level:•A comprehensive update of oral and gastrointestinal tract mucositis guidelines previously produced by the Mucositis Study Group of MASCC in 2007 [2.Keefe D.M. Schubert M.M. Elting L.S. et al.Updated clinical practice guidelines for the prevention and treatment of mucositis.Cancer. 2007; 109: 820-831Crossref PubMed Scopus (606) Google Scholar]. The most recent updated evidence-based guidelines, published in 2014 [3.Lalla R.V. Bowen J. Barasch A. et al.MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy.Cancer. 2014; 120: 1453-1461Crossref PubMed Scopus (714) Google Scholar], represent the state-of-the-science for mucositis management in patients receiving conventional chemotherapy and/or head and neck radiation.•Expert opinion on the management of mucosal injury caused by targeted cancer therapies such as vascular endothelial growth factor receptor (VEGFR) inhibitor, epidermal growth factor receptor (EGFR) inhibitors, (multi-targeted) tyrosine kinase inhibitors (TKIs), and mammalian target of rapamycin (mTOR) inhibitors [4.Boers-Doets C.B. Raber-Durlacher J.E. Treister N.S. et al.Mammalian target of rapamycin inhibitor-associated stomatitis.Future Oncol. 2013; 9: 1883-1892Crossref PubMed Scopus (59) Google Scholar]. Since oral complaints associated with mTOR inhibitors have been studied in detail, we are able to provide more in depth information about this specific side-effect. From other targeted treatments such as BRAF-, PARP-, CTLA4-, and MEK inhibitors there is no expert consensus available upon which to base recommendations or suggestions for treatment.•Novel approaches to enteral nutrition in patients receiving head and neck radiation [5.Nugent B. Lewis S. O'Sullivan J.M. Enteral feeding methods for nutritional management in patients with head and neck cancers being treated with radiotherapy and/or chemotherapy.Cochrane Database Syst Rev. 2013; 1: CD007904Crossref PubMed Scopus (64) Google Scholar, 6.Koyfman S.A. Adelstein D.J. Enteral feeding tubes in patients undergoing definitive chemoradiation therapy for head-and-neck cancer: a critical review.Intl J Radiat Oncol Biol Phys. 2012; 84: 581-589Abstract Full Text Full Text PDF PubMed Scopus (67) Google Scholar, 7.Williams G.F. Teo M.T. Sen M. et al.Enteral feeding outcomes after chemoradiotherapy for oropharynx cancer: a role for a prophylactic gastrostomy?.Oral Oncol. 2012; 48: 434-440Crossref PubMed Scopus (45) Google Scholar, 8.Rutter C.E. Yovino S. Taylor R. et al.Impact of early percutaneous endoscopic gastrostomy tube placement on nutritional status and hospitalization in patients with head and neck cancer receiving definitive chemoradiation therapy.Head Neck. 2011; 33: 1441-1447Crossref PubMed Scopus (62) Google Scholar, 9.Silander E. Nyman J. Bove M. et al.Impact of prophylactic percutaneous endoscopic gastrostomy on malnutrition and quality of life in patients with head and neck cancer: a randomized study.Head Neck. 2012; 34: 1-9Crossref PubMed Scopus (160) Google Scholar]. In France and French-speaking countries, the Société Francophone de Nutrition et Métabolisme (SFNEP) and the Association Francophone pour les Soins Oncologiques de Support (AFSOS) published comprehensive recommendations for cancer patients [10.SFNEP (Societe Francophone de Nutrition Enterale et Parenterale) SFNEP Oncology Nutrition Guidelines.Nutrition Clinique et Métabolisme. 2012; 26 (20 April 2015, date last accessed)http://www.em-consulte.com/revue/NUTCLI/26/4/table-des-matieres/Google Scholar, 11.Bachmann P. Romero G. Deneuve S. et al.Référentiel de pratiques professionnelles: prise en charge nutritionnelle des cancers des voies a
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“probiotics containing Lactobacillus species are suggested be used to prevent diarrhea in patients receiving chemotherapy and/or radiation therapy for a pelvic malignancy (Level of evidence III) [193,194].”
From Gut Microbiota and Cancer: From Pathogenesis to Therapy (2019) · cites this paper as [193]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stool form scale as a useful guide to intestinal transit time
Lewis, S. J., & Heaton, K. W. (1997) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365529709011203 · Cited by 3,244
Nutting, C. M., Morden, J. P., Harrington, K. J., Urbano, T. G., Bhide, S. A., Clark, C., Miles, E. A., Miah, A. B., Newbold, K., Tanay, M., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70290-4 · Cited by 1,706
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy
Elad, S., Cheng, K. K. F., Lalla, R. V., Yarom, N., Hong, C., Logan, R. M., Bowen, J., Gibson, R., Saunders, D. P., Zadik, Y., et al. (2020) · Cancer · doi:10.1002/cncr.33100 · Cited by 1,336
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy
Lalla, R. V., Bowen, J., Barasch, A., Elting, L., Epstein, J., Keefe, D. M., McGuire, D. B., Migliorati, C., Nicolatou‐Galitis, O., Peterson, D. E., et al. (2014) · Cancer · doi:10.1002/cncr.28592 · Cited by 1,110
Self-citationUpdated clinical practice guidelines for the prevention and treatment of mucositis
Keefe, D. M., Schubert, M. M., Elting, L. S., Sonis, S. T., Epstein, J. B., Raber‐Durlacher, J. E., Migliorati, C. A., McGuire, D. B., Hutchins, R. D., & Peterson, D. E. (2007) · Cancer · doi:10.1002/cncr.22484 · Cited by 784
Self-citationManagement of oral and gastrointestinal mucositis: ESMO Clinical Practice Guidelines
Peterson, D. E., Bensadoun, R.-J., & Roila, F. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr391 · Cited by 305
Self-citationScully, C. (2006) · New England Journal of Medicine · doi:10.1056/nejmcp054630 · Cited by 259
Systematic review of basic oral care for the management of oral mucositis in cancer patients
On behalf of the Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO), McGuire, D. B., Fulton, J. S., Park, J., Brown, C. G., Correa, M. E. P., Eilers, J., Elad, S., Gibson, F., Oberle-Edwards, L. K., et al. (2013) · Supportive Care in Cancer · doi:10.1007/s00520-013-1942-0 · Cited by 256
FDA Approval Summary: Temsirolimus as Treatment for Advanced Renal Cell Carcinoma
Kwitkowski, V. E., Prowell, T. M., Ibrahim, A., Farrell, A. T., Justice, R., Mitchell, S. S., Sridhara, R., & Pazdur, R. (2010) · The Oncologist · doi:10.1634/theoncologist.2009-0178 · Cited by 254
Silander, E., Nyman, J., Bove, M., Johansson, L., Larsson, S., & Hammerlid, E. (2012) · Head & Neck · doi:10.1002/hed.21700 · Cited by 216
Nugent, B., Lewis, S., & O'Sullivan, J. M. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007904.pub3 · Cited by 204
Eilers, R. E., Gandhi, M., Patel, J. D., Mulcahy, M. F., Agulnik, M., Hensing, T., & Lacouture, M. E. (2010) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djp439 · Cited by 167
Sonis, S., Treister, N., Chawla, S., Demetri, G., & Haluska, F. (2010) · Cancer · doi:10.1002/cncr.24696 · Cited by 161
Oral complications of targeted cancer therapies: A narrative literature review
Watters, A. L., Epstein, J. B., & Agulnik, M. (2011) · Oral Oncology · doi:10.1016/j.oraloncology.2011.03.028 · Cited by 157
Clinical presentation and management of mTOR inhibitor-associated stomatitis
de Oliveira, M. A., Martins, F., Wang, Q., Sonis, S. T., Demetri, G. D., George, S., Butrynski, J. E., & Treister, N. S. (2011) · Oral Oncology · doi:10.1016/j.oraloncology.2011.08.009 · Cited by 131
Rugo, H. S., Pritchard, K. I., Gnant, M., Noguchi, S., Piccart, M., Hortobagyi, G., Baselga, J., Perez, A., Geberth, M., Csoszi, T., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu009 · Cited by 130
Clinical Efficacy and Toxicity of Anti-EGFR Therapy in Common Cancers
Harandi, A., Zaidi, A. S., Stocker, A. M., & Laber, D. A. (2009) · Journal of Oncology · doi:10.1155/2009/567486 · Cited by 116
Kajiya, K., Sawane, M., Huggenberger, R., & Detmar, M. J. (2008) · Journal of Investigative Dermatology · doi:10.1038/jid.2008.351 · Cited by 114
Boers-Doets, C. B., Epstein, J. B., Raber‐Durlacher, J. E., Ouwerkerk, J., Logan, R. M., Brakenhoff, J. A. C., Lacouture, M. E., & Gelderblom, H. A. J. (2011) · The Oncologist · doi:10.1634/theoncologist.2011-0111 · Cited by 102
Self-citationCooperstein, E., Gilbert, J., Epstein, J. B., Dietrich, M. S., Bond, S. M., Ridner, S. H., Wells, N. L., Cmelak, A. J., & Murphy, B. A. (2011) · Head & Neck · doi:10.1002/hed.21816 · Cited by 98
Rutter, C. E., Ellsworth, S. G., Taylor, R., Wolf, J. S., Cullen, K. J., Ord, R. A., Athas, M., Zimrin, A. B., Strome, S. E., & Suntharalingam, M. (2010) · Head & Neck · doi:10.1002/hed.21624 · Cited by 90
Koyfman, S. A., & Adelstein, D. J. (2012) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2012.03.053 · Cited by 83
Mammalian Target of Rapamycin Inhibitor-Associated Stomatitis
Boers-Doets, C. B., Raber-Durlacher, J. E., Treister, N. S., Epstein, J. B., Arends, A. B., Wiersma, D. R., Lalla, R. V., Logan, R. M., van Erp, N. P., & Gelderblom, H. (2013) · Future Oncology · doi:10.2217/fon.13.141 · Cited by 82
Self-citationManaging Stomatitis in Patients Treated With Mammalian Target of Rapamycin Inhibitors
Pilotte, A. P., Hohos, M., Polson, K., Huftalen, T. M., & Treister, N. S. (2011) · Clinical journal of oncology nursing · doi:10.1188/11.cjon.e83-e89 · Cited by 72
Sénesse, P., Bachmann, P., Bensadoun, R., Besnard, I., Bourdel‐Marchasson, I., Bouteloup, C., Crenn, P., Goldwasser, F., Guérin, O., Latino‐Martel, P., et al. (2014) · Digestive and Liver Disease · doi:10.1016/j.dld.2014.01.160 · Cited by 71
Self-citationTargeted therapy-induced diarrhea: A review of the literature
Pessi, M. A., Zilembo, N., Haspinger, E. R., Molino, L., Cosimo, S. D., Garassino, M. C., & Ripamonti, C. I. (2013) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2013.11.008 · Cited by 61
Venkatesh, G. H., Vadhiraja, B. M., Mumbrekar, K. D., Negi, H., Fernandes, D. J., Sharan, K., Banerjee, S., & Sadashiva, S. R. B. (2014) · PLoS ONE · doi:10.1371/journal.pone.0089079 · Cited by 61
Elting, L. S., Chang, Y.-C., Parelkar, P., Boers-Doets, C. B., Michelet, M., Hita, A. G., Rouleau, T., Cooksley, C. D., Halm, J. K., Vithala, M. V., et al. (2013) · Supportive Care in Cancer · doi:10.1007/s00520-013-1821-8 · Cited by 60
Self-citationWilliams, G. F., Teo, M. T. W., Şen, M., Dyker, K. E., Coyle, C., & Prestwich, R. J. D. (2011) · Oral Oncology · doi:10.1016/j.oraloncology.2011.11.022 · Cited by 55
Oral mucosal injury caused by cancer therapies: current management and new frontiers in research
Jensen, S. B., & Peterson, D. E. (2013) · Journal of Oral Pathology and Medicine · doi:10.1111/jop.12135 · Cited by 54
Self-citationSonis, S. T., Antin, J. H., Tedaldi, M., & Alterovitz, G. (2013) · Oral Diseases · doi:10.1111/odi.12146 · Cited by 51
Temsirolimus, an mTOR Inhibitor for Treatment of Patients With Advanced Renal Cell Carcinoma
Malizzia, L., & Hsu, A. D. (2008) · Clinical journal of oncology nursing · doi:10.1188/08.cjon.639-646 · Cited by 49
Peterson, D. E., Keefe, D. M. K., & Sonis, S. T. (2012) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2012.32.46 · Cited by 37
Self-citationEGFR Inhibitor-Associated Acneiform Folliculitis: Assessment and Management
Duvic, M. A. (2008) · American Journal of Clinical Dermatology · doi:10.2165/00128071-200809050-00002 · Cited by 35
Amitay‐Laish, I., David, M., & Stemmer, S. M. (2010) · The Oncologist · doi:10.1634/theoncologist.2010-0063 · Cited by 33
Li, E., & Trovato, J. A. (2012) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp100531 · Cited by 30
Handling side-effects of targeted therapies: safety of targeted therapies in solid tumours
Élez, E., Macarulla, T. M., & Tabernero, J. M. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn476 · Cited by 12
Roigas, J. (2008) · European Urology Supplements · doi:10.1016/j.eursup.2008.06.004 · Cited by 11
The potential successes and challenges of targeted anticancer therapies
Keefe, D. M. K., & Stringer, A. M. (2010) · Current Opinion in Supportive and Palliative Care · doi:10.1097/spc.0b013e3283357619 · Cited by 6
Bachmann, P., Romero, G., Deneuve, S., Bertrand, P. C., Guex, E., Caldari, D., Thibault, R., Zeanandin, G., & Quilliot, D. (2014) · Nutrition Clinique et Métabolisme · doi:10.1016/j.nupar.2014.03.003 · Cited by 4
Research works printed but not linked: 3
- 2012, SFNEP (Societe Francophone de Nutrition Enterale et Parenterale) SFNEP Oncology Nutrition Guidelines, Nutrition Clinique et Métabolisme, 26
- Boers-Doets, 2013, The mIAS scale: a scale to measure mTOR inhibitor-associated stomatitis, Support Care Cancer, 21, S140
- Somerfield, 2000, ASCO clinical practice guidelines: process, progress, pitfalls, and prospects, Class Pap Curr Comments, 4, 881
Cited by
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
Cardoso, F., Costa, A., Senkus, E., Aapro, M., André, F., Barrios, C. H., Bergh, J., Bhattacharyya, G., Biganzoli, L., Cardoso, M. J., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdw544 · Cited by 2,033
4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)
Cardoso, F., Senkus, E., Costa, A., Papadopoulos, E., Aapro, M., André, F., Harbeck, N., Aguilar Lopez, B., Barrios, C. H., Bergh, J., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy192 · Cited by 1,171
Self-citationOral mucositis: the hidden side of cancer therapy
Pulito, C., Cristaudo, A., Porta, C. L., Zapperi, S., Blandino, G., Morrone, A., & Strano, S. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01715-7 · Cited by 468
Gut Microbiota and Cancer: From Pathogenesis to Therapy
Vivarelli, S., Salemi, R., Candido, S., Falzone, L., Santagati, M., Stefani, S., Torino, F., Banna, G. L., Tonini, G., & Libra, M. (2019) · Cancers · doi:10.3390/cancers11010038 · Cited by 586
Lacouture, M., & Sibaud, V. (2018) · American Journal of Clinical Dermatology · doi:10.1007/s40257-018-0384-3 · Cited by 364
Metadata
- Authors
- Peterson, D. E., Boers-Doets, C. B., Bensadoun, R. J., & Herrstedt, J.
- Affiliations
- UConn Health (US)
- Leiden University Medical Center (NL)
- Centre de Haute Energie (FR)
- University of Southern Denmark (DK)
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2015-09
- Volume
- 26
- Pages
- v139-v151
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2149050045
- Cited by
- 299
- References
- 40
- Citations by year
- 2026: 18 · 2025: 33 · 2024: 39 · 2023: 40 · 2022: 30 · 2021: 36 · 2020: 29 · 2019: 22 · 2018: 21 · 2017: 19 · 2016: 7 · 2015: 3
- FWCI
- 13.17
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- other-oa
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 1575 d)
- Locations
- Annals of Oncology (publishedVersion, other-oa)
- PubMed (publishedVersion)
- University of Southern Denmark Research Portal (University of Southern Denmark) (submittedVersion)
- Topics
- Health Sciences › Dentistry › General Dentistry › Oral health in cancer treatment
- Health Sciences › Dentistry › General Dentistry › Oral Health Pathology and Treatment
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Chemotherapy-induced organ toxicity mitigation
- Keywords
- mucositis, oral mucositis, gastrointestinal mucositis, high-dose chemotherapy, radiotherapy-induced mucositis, mucositis prevention, mucositis treatment, cancer supportive care, head and neck cancer, ESMO guidelines
- MeSH terms
- Humans, Mouth Mucosa, Disease Management, Gastrointestinal Tract, Mucositis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.